A very insightful panel at the EPA lconference in Amsterdam from Gavin Lewis of Novartis, Annett...

A very insightful panel at the EPA conference in Amsterdam from Gavin Lewis of Novartis, Annette Zoe Powers of BMS, Arup Pramanik MD, MSc, MBA of BI, Sandro Cesaro of AZ, Christina Stentoft Hoxer of NovoNordisk on how are global healthcare reforms impacting local market access strategy. Very clearly the modeling demands are becoming more challenging, and joined Health Technology Assessments (HTA) are increasingly becoming the rule.

In every region in the world, Europe, increasingly the US (IRA), but now also Asian countries like China and Japan, healthcare and social security budget pressures are becoming more and more of a challenge for pharma companies.

Tools like JCA are becoming a new standard, but coming on top of increasing local data submission requirements.

This requires effective collaboration between the different teams in market access and clinical development. Furthermore, PICOs need to be integrated into the target product profiles as of phase II at the latest, and ensure your clinical program is structured accordingly. This will also increase the need for true RWE.

It will be very interesting to watch how the IRA in the US will trigger increased transparency around the rather opaque and complex PBM system.

Gavin summarized it nicely, increasingly your access strategy becomes your entire enterprise strategy.

He also expects that in the next 5 years AI will be able to play a significant role in helping us make predictions to inform the market access strategy.

epaconf World Evidence, Pricing and Access Congress